UA83542C2 - Комбинация агомелатина и ингибитора обратного захвата норадреналина и содержащая ее фармацевтическая композиция - Google Patents
Комбинация агомелатина и ингибитора обратного захвата норадреналина и содержащая ее фармацевтическая композиция Download PDFInfo
- Publication number
- UA83542C2 UA83542C2 UAA200609700A UAA200609700A UA83542C2 UA 83542 C2 UA83542 C2 UA 83542C2 UA A200609700 A UAA200609700 A UA A200609700A UA A200609700 A UAA200609700 A UA A200609700A UA 83542 C2 UA83542 C2 UA 83542C2
- Authority
- UA
- Ukraine
- Prior art keywords
- agomelatin
- inhibitor
- combination
- pharmaceutical composition
- noradrenaline reuptake
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000000966 norepinephrine reuptake Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 4
- 229960002629 agomelatine Drugs 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229960003770 reboxetine Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0509206A FR2890564B1 (fr) | 2005-09-09 | 2005-09-09 | Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA83542C2 true UA83542C2 (ru) | 2008-07-25 |
Family
ID=36190808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200609700A UA83542C2 (ru) | 2005-09-09 | 2006-09-08 | Комбинация агомелатина и ингибитора обратного захвата норадреналина и содержащая ее фармацевтическая композиция |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US7622505B2 (ru) |
| EP (1) | EP1769798B1 (ru) |
| JP (2) | JP5395998B2 (ru) |
| KR (1) | KR100863384B1 (ru) |
| CN (1) | CN1927205A (ru) |
| AP (1) | AP2615A (ru) |
| AR (1) | AR056056A1 (ru) |
| AT (1) | ATE404205T1 (ru) |
| AU (1) | AU2006209368B2 (ru) |
| BR (1) | BRPI0603759A (ru) |
| CA (1) | CA2558782C (ru) |
| CY (1) | CY1108319T1 (ru) |
| DE (1) | DE602006002210D1 (ru) |
| DK (1) | DK1769798T3 (ru) |
| EA (1) | EA011650B1 (ru) |
| ES (1) | ES2313590T3 (ru) |
| FR (1) | FR2890564B1 (ru) |
| GE (1) | GEP20094742B (ru) |
| GT (1) | GT200600408A (ru) |
| HR (1) | HRP20080535T3 (ru) |
| JO (1) | JO2521B1 (ru) |
| MA (1) | MA28505B1 (ru) |
| ME (2) | ME02758B (ru) |
| MX (1) | MXPA06010157A (ru) |
| MY (1) | MY142260A (ru) |
| NO (1) | NO338029B1 (ru) |
| NZ (1) | NZ549725A (ru) |
| PE (1) | PE20070429A1 (ru) |
| PL (1) | PL1769798T3 (ru) |
| PT (1) | PT1769798E (ru) |
| RS (1) | RS50631B (ru) |
| SA (1) | SA06270308B1 (ru) |
| SG (1) | SG131030A1 (ru) |
| SI (1) | SI1769798T1 (ru) |
| TW (1) | TWI324513B (ru) |
| UA (1) | UA83542C2 (ru) |
| UY (1) | UY29778A1 (ru) |
| WO (1) | WO2007028904A1 (ru) |
| ZA (1) | ZA200607562B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008247805A1 (en) * | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Naphthyl(ethyl) acetamides |
| WO2008141033A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals Inc. | Substituted naphthalenes |
| CN102342924A (zh) * | 2010-08-05 | 2012-02-08 | 北京本草天源药物研究院 | 一种含有阿戈美拉汀的药物组合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ZA985765B (en) * | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| ZA989251B (en) * | 1997-10-17 | 2000-04-10 | Lilly Co Eli | Potentiation of pharmaceuticals. |
| FR2834890B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'agomelatine |
| JP2005518439A (ja) * | 2002-02-26 | 2005-06-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬 |
| JP2004292445A (ja) * | 2003-03-11 | 2004-10-21 | Katsunori Nonogaki | 糖尿病治療薬 |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| AU2004271796A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders |
-
2005
- 2005-09-09 FR FR0509206A patent/FR2890564B1/fr not_active Expired - Fee Related
-
2006
- 2006-08-22 MA MA29281A patent/MA28505B1/fr unknown
- 2006-08-31 EA EA200601410A patent/EA011650B1/ru not_active IP Right Cessation
- 2006-08-31 UY UY29778A patent/UY29778A1/es not_active Application Discontinuation
- 2006-08-31 SG SG200605974-5A patent/SG131030A1/en unknown
- 2006-09-04 CN CNA2006101289194A patent/CN1927205A/zh active Pending
- 2006-09-04 PE PE2006001067A patent/PE20070429A1/es not_active Application Discontinuation
- 2006-09-06 SA SA06270308A patent/SA06270308B1/ar unknown
- 2006-09-06 BR BRPI0603759-3A patent/BRPI0603759A/pt not_active Application Discontinuation
- 2006-09-07 MY MYPI20064102A patent/MY142260A/en unknown
- 2006-09-07 GE GEAP20069612A patent/GEP20094742B/en unknown
- 2006-09-07 US US11/516,877 patent/US7622505B2/en not_active Expired - Fee Related
- 2006-09-07 NZ NZ549725A patent/NZ549725A/en not_active IP Right Cessation
- 2006-09-07 JO JO2006305A patent/JO2521B1/en active
- 2006-09-07 MX MXPA06010157A patent/MXPA06010157A/es active IP Right Grant
- 2006-09-08 ME MEP-2008-631A patent/ME02758B/me unknown
- 2006-09-08 RS RSP-2008/0504A patent/RS50631B/sr unknown
- 2006-09-08 ZA ZA200607562A patent/ZA200607562B/xx unknown
- 2006-09-08 DE DE602006002210T patent/DE602006002210D1/de active Active
- 2006-09-08 SI SI200630102T patent/SI1769798T1/sl unknown
- 2006-09-08 AR ARP060103907A patent/AR056056A1/es not_active Application Discontinuation
- 2006-09-08 CA CA2558782A patent/CA2558782C/fr not_active Expired - Fee Related
- 2006-09-08 UA UAA200609700A patent/UA83542C2/ru unknown
- 2006-09-08 ES ES06291421T patent/ES2313590T3/es active Active
- 2006-09-08 GT GT200600408A patent/GT200600408A/es unknown
- 2006-09-08 PT PT06291421T patent/PT1769798E/pt unknown
- 2006-09-08 DK DK06291421T patent/DK1769798T3/da active
- 2006-09-08 EP EP06291421A patent/EP1769798B1/fr active Active
- 2006-09-08 WO PCT/FR2006/002067 patent/WO2007028904A1/fr active Application Filing
- 2006-09-08 AP AP2008004378A patent/AP2615A/xx active
- 2006-09-08 ME MEP-2008-504A patent/ME02767B/me unknown
- 2006-09-08 TW TW095133159A patent/TWI324513B/zh not_active IP Right Cessation
- 2006-09-08 AT AT06291421T patent/ATE404205T1/de active
- 2006-09-08 PL PL06291421T patent/PL1769798T3/pl unknown
- 2006-09-08 AU AU2006209368A patent/AU2006209368B2/en not_active Ceased
- 2006-09-08 NO NO20064048A patent/NO338029B1/no not_active IP Right Cessation
- 2006-09-11 JP JP2006245009A patent/JP5395998B2/ja not_active Expired - Fee Related
- 2006-09-11 KR KR1020060087622A patent/KR100863384B1/ko active IP Right Grant
-
2008
- 2008-09-04 CY CY20081100955T patent/CY1108319T1/el unknown
- 2008-11-05 HR HR20080535T patent/HRP20080535T3/xx unknown
-
2010
- 2010-12-21 JP JP2010284300A patent/JP2011088919A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070060655A1 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient | |
| CA2777746A1 (en) | Benzoimidazole compounds and uses thereof | |
| UA83542C2 (ru) | Комбинация агомелатина и ингибитора обратного захвата норадреналина и содержащая ее фармацевтическая композиция | |
| JP2021502392A5 (ru) | ||
| RU2006104009A (ru) | Фармацевтическая препаративная форма | |
| DK2533774T3 (en) | USE OF AGOMELATIN FOR THE PREPARATION OF MEDICINALS FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE CONDITION (OCD) | |
| US7947743B2 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders | |
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| RU2008105972A (ru) | Новая соль i | |
| US7902180B2 (en) | Association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it | |
| Islam | An overview: extent of teratogenicity of common medications in fetal development | |
| Cusin et al. | Original Research A Randomized, Double-Blind, Placebo-Controlled Trial | |
| JP2005527634A (ja) | 緊張型頭痛の治療にミルナシプランを使用する方法 | |
| JANCIN | Tricyclics Elevate Metabolic Syndrome Risk | |
| EP2046119A2 (en) | Treatment of psychiatric disorders | |
| RU2014127731A (ru) | Комбинация 4-{ 3-[цис-гексагидроциклопента[c]пиррол-2(1н)-ил]пропокси} бензамида и антагониста nmda-рецептора и содержащие ее фармацевтические композиции |